Phase 2 N=2 LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=77 Dose Escalation Study for Primary Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Number of Patients With DLTs — 0; 2; 1; 0 Participants
N/A N=76 Adjuvant Radiotherapy for Resected Hepatocellular Carcinoma With MVI
Hepatocellular Carcinoma
Primary: Participants Without Recurrence (Disease-free). — 16; 28 Participants
Phase 2 N=32 Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Participants With Objective Response Rate — 20; 9; 0; 1 Participants
Phase 2 N=146 A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
Liver Cancer · Hepatocellular Cancer
Primary: The Percentage of Patients With Local Control at 1 Year Post Treatment — 99 percentage of patients
N/A N=23 Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Phase 2 N=12 [68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Number of Patients Demonstrating Somatostatin Receptor Positivity in Hepatocellular Carcinoma Using [68Ga]DOTATATE-PET — 0 Participants
N/A N=76 Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
Phase 2 N=47 Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
Hepatocellular Carcinoma · Liver Cancer
Primary: Median Radiographic Time to Progression (TTP) Calculated From Treatment Initiation to First Evidence of Disease Progression or Last Follow-up. — 6.7 months
N/A N=105 Primary Cell Culture of Hepatic Tumorous Cells From Routine Fine-needle Aspiration
Hepatocellular Carcinoma
Primary: Correlation Between the Growth Speeds of the Cultured Cells and the AJCC TNM Stage (7th Eds) at Entering of the Study. — 21; 29; 14; 9 participants — p=< 0.005
N/A N=109 STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Localized Hepatocellular Carcinoma
Primary: Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging) — 75; 73 participants
N/A N=29 Impact of Y90 Radiation Segmentectomy on HCC
Hepatocellular Carcinoma
Primary: Number of Participants With Local Tumor Response According to mRECIST — 26; 0; 0; 3 Participants
Phase 2 N=24 Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Success of DEBDOX-M1 Procedure as a Measure of Feasibility — 100 percentage of successful treatments
Early Phase 1 N=17 A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Primary: Safety of a Combination Therapy — 0 participants
N/A N=84 Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)
Hepatocellular Carcinoma · HCC
Primary: SubStudy 1: Apparent Diffusion Coefficient (ADC) — 1.43 1x10^-3 mm^2/s
Phase 2 N=20 Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
Hepatocellular Cancer
Primary: Coagulation Zone Diameter-Short Axis — 36.0; 35.1 millimeters
Phase 2 N=76 Proton Beam Therapy for Treatment of Hepatocellular Carcinoma
Liver Cancer · Hepatocellular Carcinoma
Primary: 3-year Survival Without Tumor Progression for Patients Within the Milan Criteria — 60 percentage of participants
Phase 2 N=60 Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular Carcinoma
Primary: Progression-Free Survival(PFS) — 5.7; 2.7 months — p=<0.001
Phase 2 N=172 PI-88 in Hepatocellular Carcinoma After Hepatectomy
Carcinoma, Hepatocellular
Primary: Tumour Non-recurrence Rate — 32; 40; 35 Participants — p=0.072
Phase 3 N=70 De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
Liver Carcinoma
Primary: Percentage of Participants Surviving at One and Four Years After Liver Transplant — 85; 77 percentage of participants
Phase 2 N=41 Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial
Liver Cancer
Primary: Response Rate by Recist Criteria — 6 participants
Phase 3 N=701 Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant…
Phase 3 N=554 Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 58.06; NA Months
Phase 2 N=26 Study of Pembrolizumab Following TACE in Primary Liver Carcinoma
Primary Liver Carcinoma
Primary: Incidence of Treatment-emergent Adverse Events (Safety and Tolerability) — 15 Participants
Phase 4 N=96 Hepatic Xenetix-CT Perfusion
Hepatocellular Carcinoma
Primary: Blood Volume (BV) According to Degree of Lesions Differentiation — 15.930; 13.958 mL/100 grams
Phase 2 N=30 IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 4 Participants
Phase 2 N=20 Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
N/A N=131 Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC
Advanced Hepatocellular Carcinoma
Primary: Percentage of Lesions With Organ-specific Response — 29.8; 28.3; 40.5; 29.1 Percentage of Units (lesions)
Phase 2 N=76 A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma
Hepatocellular Carcinoma · Liver Cancer
Primary: Tumor Response — 0; 7; 47; 11 Participants
N/A N=14 Advanced Image Guidance Utilized in Liver Surgery
Carcinoma, Hepatocellular
Primary: Successful Insertion of Ablation Antenna Into Target Lesion — 100 percentage of participants